ArticlePloS one2012
Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Pro-repair properties of a human embryonic stem cell-derived astrocyte cell therapy in demyelinating disorders.Stem cell reports · 2026Article
- Artificial activation of clinically failed human oocytes enables euploid blastocyst formation.Journal of assisted reproduction and genetics · 2026Article
- Pneumatospinning and Electrospinning Scaffolds for Meniscus Regeneration Using Human Embryonic-Derived Mesenchymal Stem Cells.Bioengineering (Basel, Switzerland) · 2026Article
- Anti-Inflammatory and Angiogenic Effects of Stem Cell Secretome.International journal of molecular sciences · 2026Article
- Pluripotent stem cell lines available for use in clinical applications: A comprehensive overview.Stem cell reports · 2026Review
- A simple and standardized method supports efficient derivation of clinical-grade human embryonic stem cells under feeder- and xeno-free conditions.Stem cell research & therapy · 2025Article
- Challenges Facing the Translation of Embryonic Stem Cell Therapy for the Treatment of Cartilage Lesions.Stem cells translational medicine · 2022Review
- Laminin111-based defined culture promoting self-renewing human pluripotent stem cells with properties of the early post-implantation epiblast.Stem cell reports · 2022Article
- Efficient derivation and banking of clinical-grade human embryonic stem cell lines in accordance with Japanese regulations.Regenerative therapy · 2022Article
- The Manufacture of Xeno- and Feeder-Free Clinical-Grade Human Embryonic Stem Cell Lines: First Step for Cell Therapy.International journal of molecular sciences · 2022Article
- Advances in hPSC expansion towards therapeutic entities: A review.Cell proliferation · 2022Review
- Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.Cell proliferation · 2022Article
- Manufacturing clinical-grade human induced pluripotent stem cell-derived beta cells for diabetes treatment.Cell proliferation · 2022Review
- Semi-3D cultures using Laminin 221 as a coating material for human induced pluripotent stem cells.Regenerative biomaterials · 2022Article
- Selection for CD26Frontiers in endocrinology · 2021Article
- Human Placenta-Derived ECM Supports Tri-Lineage Differentiation of Human Induced Pluripotent Stem Cells.International journal of stem cells · 2020Article
- A Manually Curated Database on Clinical Studies Involving Cell Products Derived from Human Pluripotent Stem Cells.Stem cell reports · 2020Article
- Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy.International journal of molecular sciences · 2020Review
- Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity.EBioMedicine · 2019Article
- Stem cells: past, present, and future.Stem cell research & therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically compliant human embryonic stem cells (hESCs) should be developed in adherence to ethical standards, without risk of contamination by adventitious agents. Here we developed for the first time animal-component free and good manufacturing practice (GMP)-compliant hESCs. After vendor and raw material qualification, we derived xeno-free, GMP-grade feeders from umbilical cord tissue, and utilized them within a novel, xeno-free hESC culture system. We derived and characterized three hESC lines in adherence to regulations for embryo procurement, and good tissue, manufacturing and laboratory practices. To minimize freezing and thawing, we continuously expanded the lines from initial outgrowths and samples were cryopreserved as early stocks and banks. Batch release criteria included DNA-fingerprinting and HLA-typing for identity, characterization of pluripotency-associated marker expression, proliferation, karyotyping and differentiation in-vitro and in-vivo. These hESCs may be valuable for regenerative therapy. The ethical, scientific and regulatory methodology presented here may serve for development of additional clinical-grade hESCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.